Vera Therapeutics VERA Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Returns | |||||
| Return on equity | -50.7%-5.9pp | -44.8%+62.7pp | -107.5%+14.1pp | -121.6%— | |
| Return on assets | -43.1%-6.5pp | -36.6%+25.9pp | -62.5%+20.2pp | -82.8%-35.6pp | |
| Return on invested capital | -72.8%-21.3pp | -51.5%+65.6pp | -117.2%+152pp | -269.4%— | |
| Liquidity | |||||
| Current ratio | 13.6×-12.0× | 25.7×+18.0× | 7.7×+2.8× | 4.9×-5.8× | |
| Quick ratio | 13.6×-12.0× | 25.7×+18.0× | 7.7×+2.8× | 4.9×-5.8× | |
| Cash ratio | 6.6×+3.0× | 3.7×+1.6× | 2×+0.3× | 1.7×-8.7× | |
| Leverage | |||||
| Debt-to-equity | 0.1×0.0× | 0.1×-0.4× | 0.5×+0.1× | 0.4×+0.2× | |
| Debt-to-assets | 0.1×0.0× | 0.1×-0.2× | 0.3×+0.1× | 0.2×+0.1× | |
| Interest coverage | -41.9×-20.0× | -21.9×+5.0× | -26.9×+64.7× | -91.6×+1,628× | |
| Per Share | |||||
| Book value per share | $9.41-9.8% | $10.43+338% | $2.38-17.7% | $2.89-44.1% | |
| Valuation | |||||
| Market capitalization | $3.59B+34.2% | $2.68B+292% | $683.67M+27.1% | $537.95M-16.9% | |
| Enterprise value | $3.32B+25.7% | $2.64B+282% | $691.7M+31.6% | $525.48M-9.5% | |
| Price / book | 5.9×+1.3× | 4.6×-2.1× | 6.7×-0.3× | 7×-2.3× | |
| Free cash flow yield | -6.7%-1.7pp | -5.1%+8.4pp | -13.5%-0.9pp | -12.6%-8.9pp | |
| Earnings yield | -8.3%-2.7pp | -5.7%+8.4pp | -14%+2.5pp | -16.6%-11.5pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Vera Therapeutics's ratios come from?
- Every ratio is computed from Vera Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.